Out Licensing

GLUETACS possesses two orally administered clinical Phase I molecular glue pipelines, GT919 and GT929, as well as five orally administered bifunctional degrader product pipelines. These are being developed to address unmet medical needs in oncology and autoimmune indications, such as multiple myeloma, non-Hodgkin lymphoma, breast cancer, prostate cancer, lung cancer, liver cancer, atopic dermatitis, lupus, psoriasis, and hidradenitis suppurativa.

Out Licensing Contact：

Email:       bd@gluetacs.com
Tel: China   +86-21-58162328
                  +86-16601792289
Tel: US         +1-9709809873
Wechat:    13388986616